MAO-B Inhibitor 58 | CAS#1619884-75-1 | MAO-B inhibitor

MedKoo Cat#: 562502 | Name: MAO-B Inhibitor 58

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MAO-B Inhibitor 58 is a highly potent, selective, competitive, and reversible inhibitor of monoamine oxidase B (MAO-B).

Chemical Structure

MAO-B Inhibitor 58

CAS#1619884-75-1

Theoretical Analysis

MedKoo Cat#: 562502

Name: MAO-B Inhibitor 58

CAS#: 1619884-75-1

Chemical Formula: C14H9Cl2N3

Exact Mass: 289.0174

Molecular Weight: 290.14

Elemental Analysis: C, 57.95; H, 3.13; Cl, 24.44; N, 14.48

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MAO-B Inhibitor 58; MAO-B Inhibitor-58;

IUPAC/Chemical Name

(E)-N-(3,4-dichlorophenyl)-(1H-indazol-5-yl)methanimine

InChi Key

ODHPFVFFVLSYBF-REZTVBANSA-N

InChi Code

InChI=1S/C14H9Cl2N3/c15-12-3-2-11(6-13(12)16)17-7-9-1-4-14-10(5-9)8-18-19-14/h1-8H,(H,18,19)/b17-7+

SMILES Code

ClC1=CC=C(/N=C/C2=CC3=C(NN=C3)C=C2)C=C1Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 290.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Strupp M, Kraus L, Schautzer F, Rujescu D. Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline-an observational study. J Neurol. 2018 Mar 12. doi: 10.1007/s00415-018-8809-8. [Epub ahead of print] PubMed PMID: 29532287. 2: Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018 Feb 19;2:CD010585. doi: 10.1002/14651858.CD010585.pub2. Review. PubMed PMID: 29457627. 3: Lan JS, Liu Y, Hou JW, Yang J, Zhang XY, Zhao Y, Xie SS, Ding Y, Zhang T. Design, synthesis and evaluation of resveratrol-indazole hybrids as novel monoamine oxidases inhibitors with amyloid-β aggregation inhibition. Bioorg Chem. 2018 Feb;76:130-139. doi: 10.1016/j.bioorg.2017.11.009. Epub 2017 Nov 15. PubMed PMID: 29172101. 4: Cao S, Ye L, Wu Y, Mao B, Chen L, Wang X, Huang P, Su Y, Ge RS. The Effects of Fungicides on Human 3β-Hydroxysteroid Dehydrogenase 1 and Aromatase in Human Placental Cell Line JEG-3. Pharmacology. 2017;100(3-4):139-147. doi: 10.1159/000475531. Epub 2017 Jun 22. PubMed PMID: 28637041. 5: Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, Pauly-Evers M, Nikolcheva T, Czech C, Borroni E, Ricci B, Dukart J, Mannino M, Carey T, Moran E, Gilaberte I, Muelhardt NM, Gerlach I, Santarelli L, Ostrowitzki S, Fontoura P. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017;58(4):1217-1228. doi: 10.3233/JAD-161309. PubMed PMID: 28550255; PubMed Central PMCID: PMC5523913. 6: Schipper P, Vanmolkot L, Peeters FP. [Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: a case report and literature review]. Tijdschr Psychiatr. 2016;58(12):886-890. Review. Dutch. PubMed PMID: 27976787. 7: Desideri N, Proietti Monaco L, Fioravanti R, Biava M, Yáñez M, Alcaro S, Ortuso F. (E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors. Eur J Med Chem. 2016 Jul 19;117:292-300. doi: 10.1016/j.ejmech.2016.03.081. Epub 2016 Mar 29. PubMed PMID: 27135371. 8: Qiu Y, Huang Y, Ma X. [Effect of phenelzine on the proliferation, apoptosis and histone methylation and acetylation of Molt-4 cells]. Zhonghua Xue Ye Xue Za Zhi. 2016 Feb;37(2):144-8. doi: 10.3760/cma.j.issn.0253-2727.2016.02.012. Chinese. PubMed PMID: 27014985. 9: Fowler JS, Logan J, Shumay E, Alia-Klein N, Wang GJ, Volkow ND. Monoamine oxidase: radiotracer chemistry and human studies. J Labelled Comp Radiopharm. 2015 Mar;58(3):51-64. doi: 10.1002/jlcr.3247. Epub 2015 Feb 10. Review. PubMed PMID: 25678277. 10: Nayak BV, Ciftci-Yabanoglu S, Bhakat S, Timiri AK, Sinha BN, Ucar G, Soliman ME, Jayaprakash V. Monoamine oxidase inhibitory activity of 2-aryl-4H-chromen-4-ones. Bioorg Chem. 2015 Feb;58:72-80. doi: 10.1016/j.bioorg.2014.11.008. Epub 2014 Dec 3. PubMed PMID: 25506816. 11: Targum SD, Burch DJ, Asgharnejad M, Petersen T, Gomeni R, Fava M. Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients. Eur Neuropsychopharmacol. 2014 Aug;24(8):1188-95. doi: 10.1016/j.euroneuro.2014.06.003. Epub 2014 Jun 17. PubMed PMID: 25012515. 12: Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, Pinheiro SP, Macurdy TE, Shih D, Worrall C, Kelman JA. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone. Mov Disord. 2013 Apr;28(4):490-7. doi: 10.1002/mds.25351. Epub 2013 Feb 26. PubMed PMID: 23443994. 13: Kaur N, Madan R, Sharma A. Successful use of rasagiline in combination with two antidepressants: a case report. Innov Clin Neurosci. 2012 Nov;9(11-12):39-41. PubMed PMID: 23346517; PubMed Central PMCID: PMC3552466. 14: Zbroch E, Małyszko J, Małyszko J, Koc-Żórawska E, Myśliwiec M. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn. 2012;122(1-2):40-4. Epub 2012 Jan 11. PubMed PMID: 22237745. 15: Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, Magyar K, Halldin C. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011 Jan;58(1):60-8. doi: 10.1016/j.neuint.2010.10.013. Epub 2010 Nov 12. PubMed PMID: 21075154. 16: Rollema H, Wilson GG, Lee TC, Folgering JH, Flik G. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Neurochem Int. 2011 Jan;58(1):78-84. doi: 10.1016/j.neuint.2010.10.015. Epub 2010 Nov 5. PubMed PMID: 21056607. 17: Bano S, Gitay M, Ara I, Badawy A. Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pak J Pharm Sci. 2010 Jul;23(3):266-72. PubMed PMID: 20566438. 18: Orlander H, Peter S, Jarvis M, Ricketts-Hall L. Imipramine induced elevation of prolactin levels in patients with HIV/AIDS improved their immune status. West Indian Med J. 2009 Jun;58(3):207-13. PubMed PMID: 20043526. 19: Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2008 Oct;69(10):1589-601. Review. PubMed PMID: 19192442. 20: Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M, Rinne JO. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009 May;85(5):506-12. doi: 10.1038/clpt.2008.241. Epub 2009 Jan 7. PubMed PMID: 19129751.